All In Biotech

Drug Trial Radar · NCT06423911

Study of Olverembatinib (HQP1351) in Patients With CML-CP

A Global, Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 333 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

333

Planned (sponsor's estimate)

Start

Feb 5, 2024

Primary completion

Jun 30, 2027

Study completion Jul 10, 2028

Sponsor

Lead sponsor
Ascentage Pharma Group Inc.Industry
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study comparing efficacy and safety of olverembatinib (investigational arm) vs. bosutinib (control arm) in patients with CML-CP (Part A). Study will also evaluate efficacy and safety of olverembatinib (single-arm) in CML-CP patients with T315I mutation (Part B). Patients who meet ELN 2025 failure criteria while receiving bosutinib in Part A may be able to receive olverembatinib in crossover follow-on study.

Conditions

  • Chronic Myeloid Leukemia
  • CML
  • CML, Chronic Phase

Interventions

  • olverembatinibDrug

    olverembatinib QOD

  • BosutinibDrug

    Bosutnib QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 24-Week MMR Rate (Part A)Time frame: 24 weeks
  2. 24-Week MMR Rate (Part B)Time frame: 24 weeks

Locations

163 sites in 16 countries. Site status is shown where the registry gives one.

  • Ascentage Investigative Site #1044

    Birmingham, Alabama · Recruiting

  • Ascentage Investigative Site #1112

    Anchorage, Alaska · Recruiting

  • Ascentage Investigative Site #1111

    Goodyear, Arizona · Recruiting

  • Ascentage Investigative Site #1062

    Duarte, California · Recruiting

  • Ascentage Investigative Site #1099

    Irvine, California · Recruiting

  • Ascentage Investigative Site #1075

    La Jolla, California · Recruiting

  • Ascentage Investigative Site #1100

    Long Beach, California · Recruiting

  • Ascentage Investigative Site #1059

    Los Angeles, California · Recruiting

  • Ascentage Investigative Site #1121

    Sacramento, California · Recruiting

  • Ascentage Investigative Site #1109

    Upland, California · Recruiting

  • Ascentage Investigative Site #1045

    Augusta, Georgia · Recruiting

  • Ascentage Investigative Site #1110

    Newnan, Georgia · Recruiting

  • Ascentage Investigative Site #1055

    Chicago, Illinois · Recruiting

  • Ascentage Investigative Site #1095

    Decatur, Illinois · Recruiting

  • Ascentage Investigative Site #1069

    Indianapolis, Indiana · Recruiting

  • Ascentage Investigative Site #1065

    Wichita, Kansas · Recruiting

  • Ascentage Investigative Site #1084

    Lexington, Kentucky · Recruiting

  • Ascentage Investigative Site #1058

    Louisville, Kentucky · Recruiting

  • Ascentage Investigative Site #1801

    Baltimore, Maryland · Recruiting

  • Ascentage Investigative Site #1056

    Detroit, Michigan · Recruiting

  • Ascentage Investigative Site #1023

    Detroit, Michigan · Recruiting

  • Ascentage Investigative Site #1088

    St Louis, Missouri · Recruiting

  • Ascentage Investigative Site #1097

    Lincoln, Nebraska · Not yet recruiting

  • Ascentage Investigative Site #1066

    Las Vegas, Nevada · Recruiting

  • Ascentage Investigative Site #1113

    Reno, Nevada · Recruiting

  • Ascentage Investigative Site #1064

    Hackensack, New Jersey · Recruiting

  • Ascentage Investigative Site #1054

    Morristown, New Jersey · Recruiting

  • Ascentage Investigative Site #1098

    New Brunswick, New Jersey · Recruiting

  • Ascentage Investigative Site #1072

    Albuquerque, New Mexico · Recruiting

  • Ascentage Investigative Site #1068

    Rochester, New York · Recruiting

  • Ascentage Investigative Site #1053

    Shirley, New York · Recruiting

  • Ascentage Investigative Site #1160

    Stony Brook, New York · Not yet recruiting

  • Ascentage Investigative Site #1019

    Greenville, North Carolina · Not yet recruiting

  • Ascentage Investigative Site #1043

    Morrisville, North Carolina · Recruiting

  • Ascentage Investigative Site #1173

    Cleveland, Ohio · Not yet recruiting

  • Ascentage Investigative Site #1096

    Cleveland, Ohio · Not yet recruiting

  • Ascentage Investigative Site #1174

    Mayfield Heights, Ohio · Not yet recruiting

  • Ascentage Investigative Site #1139

    Portland, Oregon · Not yet recruiting

  • Ascentage Investigative Site #1057

    Philadelphia, Pennsylvania · Recruiting

  • Ascentage Investigative Site #1022

    Pittsburgh, Pennsylvania · Recruiting

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.